("Cyprotex" or "the Company")
New DDI-Fusion Combines Chemical Structure with In Vitro Data
to Predict Human Drug-Drug Interactions.
Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today the launch of DDI-Fusion, which predicts human drug-drug interactions (DDI) from chemical structure combined with in vitro data.
Drug-drug interactions occur when multiple drugs are administered to a patient and one or more of these drugs have the ability to interact with the metabolism or transport of the co-administered drug(s), leading to changes in plasma concentrations and potentially reduced efficacy (therapeutic effect) or enhanced toxicity. The importance of DDI is growing due to our aging population and the increasing use of polypharmacy with this population and in other conditions such as cancer or HIV.
DDI-Fusion utilises Cyprotex’s chemPK™ tool to predict key pharmacokinetic parameters as inputs to the model. It combines these inputs with in vitro data related to DDI mediated via CYP3A4, one of the main drug metabolising enzymes in the body, in order to predict the potential effects on drugs metabolised by this enzyme. The software can also be used to predict interactions with other metabolising enzymes within the body. DDI-Fusion has several advantages over existing techniques in that it uses robust physiologically-based pharmacokinetic (PBPK) modelling techniques and does not require any clinical data as inputs to the model.
Dr Anthony Baxter, Cyprotex’s Chief Executive Officer, comments: “DDI-Fusion is the latest addition to a suite of powerful, interconnected in silico tools to assist scientists in decision-making early in the drug discovery process. Prediction of pharmacokinetics by chemPK™ drives the prediction of DDI by DDI-Fusion using a unique algorithm developed here at Cyprotex. The approach is logical, adaptable and robust, and performs favourably compared to the mechanistic static approach currently promoted by the regulatory authorities.”
For Further Information
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company’s core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe® PK, chemPK™, chemTarget, chemTox and DDI-Fusion and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com.